{"log_id": 6495360410912332381, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 0.000992, "average": 0.987037, "min": 0.878047}, "location": {"width": 305, "top": 127, "height": 42, "left": 135}, "words": "治疗癌痛或有内脏转移的受试者"}, {"probability": {"variance": 0.012817, "average": 0.945233, "min": 0.509144}, "location": {"width": 834, "top": 153, "height": 64, "left": 179}, "words": "共1,088例患者按1:1比例随机分配接受口服本品1000mg每日1次(n=546)或口服安慰"}, {"probability": {"variance": 0.022047, "average": 0.916366, "min": 0.469788}, "location": {"width": 876, "top": 201, "height": 64, "left": 139}, "words": "剂每日1次(n=542),两组均合并泰用泼尼松5mg每日2次。当息者出现影像学或临床细胞"}, {"probability": {"variance": 0.005954, "average": 0.970736, "min": 0.654201}, "location": {"width": 874, "top": 249, "height": 64, "left": 141}, "words": "毒化疗、放疗或手术治疗、阿片类药物治疗或ECOG状态评分在3分以上)疾病进展、不可耐"}, {"probability": {"variance": 8e-06, "average": 0.997798, "min": 0.989016}, "location": {"width": 366, "top": 316, "height": 44, "left": 143}, "words": "受的毒性或退出研究,患者将停止治疗"}, {"probability": {"variance": 8.9e-05, "average": 0.994397, "min": 0.964845}, "location": {"width": 831, "top": 344, "height": 61, "left": 188}, "words": "接受本品联合泼尼松或泼尼松龙治疗的受试者中位年龄为71岁,接受安慰剂联合泼尼松"}, {"probability": {"variance": 0.011319, "average": 0.959882, "min": 0.402343}, "location": {"width": 868, "top": 391, "height": 64, "left": 147}, "words": "或泼尼松龙治疗的受试者中位年龄为70岁。按人种分类,本品治疗组的受试者中有白人526"}, {"probability": {"variance": 0.016498, "average": 0.923551, "min": 0.50263}, "location": {"width": 880, "top": 438, "height": 65, "left": 146}, "words": "例(95.4%)、黑人15例(2.8%)、亚洲人4例(0.7%)及其他6例(1.1%)。两治疗组中76%"}, {"probability": {"variance": 0.017403, "average": 0.949519, "min": 0.412627}, "location": {"width": 876, "top": 485, "height": 64, "left": 150}, "words": "的受试者ECOG体能状态评分为0,24%的受试者评分为150%的受试者仅有骨转移,31%"}, {"probability": {"variance": 0.014881, "average": 0.958476, "min": 0.413425}, "location": {"width": 876, "top": 531, "height": 63, "left": 151}, "words": "有骨转移和软组织或淋巴结转移,19%仅患有软组织或淋巴结转移。联合主要疗效终点为总"}, {"probability": {"variance": 0.014714, "average": 0.950936, "min": 0.36699}, "location": {"width": 875, "top": 577, "height": 63, "left": 154}, "words": "生存期和影像学无进展生存期(rPF)。除此之外,还采用以下指标评估疗效:至使用阿片类药"}, {"probability": {"variance": 0.011657, "average": 0.963865, "min": 0.466508}, "location": {"width": 876, "top": 623, "height": 63, "left": 155}, "words": "物缓解癌症疼痛的时间、至细胞毒性化疗开始的时间、至E00G体能状态评分恶化时间(与基"}, {"probability": {"variance": 0.021437, "average": 0.936982, "min": 0.373577}, "location": {"width": 716, "top": 677, "height": 54, "left": 158}, "words": "线相比≥1分)至PSA进展时间(根据前列腺癌工作组2PCWG2】标准判定"}, {"probability": {"variance": 0.015338, "average": 0.959275, "min": 0.369}, "location": {"width": 816, "top": 716, "height": 61, "left": 201}, "words": "影像学无进生存期的评估采用连续的影像学检查,如骨病灶的评估采用PCWG2定义"}, {"probability": {"variance": 0.005485, "average": 0.959166, "min": 0.683099}, "location": {"width": 875, "top": 761, "height": 64, "left": 162}, "words": "软组织病灶的评估采用已改良的实体瘤疗效评价标准( RECIST1.1)。rPFS的分析采用经中心实"}, {"probability": {"variance": 0.000146, "average": 0.98887, "min": 0.957317}, "location": {"width": 262, "top": 830, "height": 42, "left": 163}, "words": "验室审查的影像学进展评估"}, {"probability": {"variance": 0.005845, "average": 0.975292, "min": 0.507865}, "location": {"width": 835, "top": 853, "height": 62, "left": 207}, "words": "根据计划的rPFS分析,共有401例受试者出现有影像学证据的进展或发生死亡事件,本品"}, {"probability": {"variance": 0.021401, "average": 0.928695, "min": 0.366147}, "location": {"width": 879, "top": 899, "height": 64, "left": 168}, "words": "治疗组150例28%)安慰剂治疗组251例(46%)两治疗组间的PFS存在显著差异(见表7"}, {"probability": {"variance": 0.020248, "average": 0.862395, "min": 0.635278}, "location": {"width": 75, "top": 978, "height": 25, "left": 172}, "words": "和图2)"}, {"probability": {"variance": 0.012664, "average": 0.9597, "min": 0.36334}, "location": {"width": 876, "top": 1025, "height": 61, "left": 173}, "words": "表7:研究302:接受本品或安慰剂联合泼尼松或泼尼松龙加HR类似物或既往睾丸切除术"}, {"probability": {"variance": 0.001191, "average": 0.980536, "min": 0.879801}, "location": {"width": 322, "top": 1089, "height": 38, "left": 231}, "words": "治疗的患者的无影像学进展生存期"}, {"probability": {"variance": 8.5e-05, "average": 0.981009, "min": 0.971767}, "location": {"width": 155, "top": 1122, "height": 37, "left": 649}, "words": "本品"}, {"probability": {"variance": 4e-06, "average": 0.997306, "min": 0.994856}, "location": {"width": 66, "top": 1117, "height": 26, "left": 887}, "words": "安慰剂"}, {"probability": {"variance": 0.004721, "average": 0.925852, "min": 0.78682}, "location": {"width": 81, "top": 1161, "height": 22, "left": 634}, "words": "N=546)"}, {"probability": {"variance": 0, "average": 0.970993, "min": 0.970993}, "location": {"width": 116, "top": 1148, "height": 34, "left": 782}, "words": "("}, {"probability": {"variance": 0.000904, "average": 0.985785, "min": 0.892595}, "location": {"width": 228, "top": 1194, "height": 35, "left": 219}, "words": "无影像学进展生存期(r"}, {"probability": {"variance": 0.000132, "average": 0.992944, "min": 0.970179}, "location": {"width": 107, "top": 1228, "height": 26, "left": 310}, "words": "进展或死亡"}, {"probability": {"variance": 0.000526, "average": 0.981546, "min": 0.938252}, "location": {"width": 102, "top": 1223, "height": 24, "left": 622}, "words": "150(28%)"}, {"probability": {"variance": 0.025648, "average": 0.607513, "min": 0.385312}, "location": {"width": 190, "top": 1173, "height": 92, "left": 863}, "words": "2【"}, {"probability": {"variance": 0.002813, "average": 0.929911, "min": 0.845032}, "location": {"width": 145, "top": 1259, "height": 26, "left": 290}, "words": "中位rPFS(月"}, {"probability": {"variance": 4e-06, "average": 0.997953, "min": 0.995263}, "location": {"width": 64, "top": 1253, "height": 26, "left": 647}, "words": "未达到"}, {"probability": {"variance": 0, "average": 0.992164, "min": 0.992164}, "location": {"width": 30, "top": 1249, "height": 23, "left": 908}, "words": "8"}, {"probability": {"variance": 3.6e-05, "average": 0.956212, "min": 0.94746}, "location": {"width": 85, "top": 1293, "height": 23, "left": 328}, "words": "95%C"}, {"probability": {"variance": 0.018933, "average": 0.922971, "min": 0.536807}, "location": {"width": 113, "top": 1285, "height": 24, "left": 620}, "words": "(11.66:NE"}, {"probability": {"variance": 0.000105, "average": 0.988376, "min": 0.973733}, "location": {"width": 46, "top": 1280, "height": 23, "left": 871}, "words": "8.12"}, {"probability": {"variance": 0.052047, "average": 0.734433, "min": 0.506296}, "location": {"width": 37, "top": 1323, "height": 25, "left": 344}, "words": "P值"}, {"probability": {"variance": 0.002969, "average": 0.967937, "min": 0.83581}, "location": {"width": 78, "top": 1315, "height": 21, "left": 757}, "words": "<0.0001"}, {"probability": {"variance": 0.032197, "average": 0.892146, "min": 0.453569}, "location": {"width": 187, "top": 1354, "height": 24, "left": 272}, "words": "风险比本(95%C1"}, {"probability": {"variance": 0.018753, "average": 0.921087, "min": 0.590014}, "location": {"width": 154, "top": 1345, "height": 29, "left": 689}, "words": "0.425(0.347"}, {"probability": {"variance": 0.047436, "average": 0.881551, "min": 0.398559}, "location": {"width": 84, "top": 1388, "height": 24, "left": 215}, "words": "NE=评估"}, {"probability": {"variance": 0.021492, "average": 0.898555, "min": 0.365252}, "location": {"width": 475, "top": 1411, "height": 34, "left": 252}, "words": "恒来自对基线ECO体能状态评分0或12的分层对数铁检验"}, {"probability": {"variance": 0.03364, "average": 0.881586, "min": 0.465192}, "location": {"width": 219, "top": 1446, "height": 30, "left": 234}, "words": "风险比一1,则本品更具优势"}], "language": 3}